Lemieux J.,of Quebec Research Center |
Lemieux J.,Deschenes Fabia Center for Breast Diseases |
Lemieux J.,University of Quebec |
Lemieux J.,Laval University |
And 21 more authors.
Anticancer Research | Year: 2013
Background: Trastuzumab has no major sideeffects except the potential for cardiac toxicity. The main objective of this study was to evaluate the association between trastuzumab-Associated cardiac toxicity and two potential risk factors: alcohol intake and HER2 polymorphisms. Patients and Methods: In a retrospective cohort study of 237 women with non-metastatic HER2- positive breast cancer treated with trastuzumab, traditional risk factors were assessed by review of medical records, alcohol use by an administered questionnaire to women (n=132), and HER2 polymorphisms (Ile655Val and Ala1170Pro) using TaqMan assays (n=73). Results: Association was observed between alcohol intake (10 drinks and more per week) during the trastuzumab treatment and cardiac toxicity (p=0.04). For polymorphisms, compared to Ile/Ile carriers, HER2 Ile/Val was associated with a higher risk of cardiac toxicity (p=0.02). Conclusion: Heavy alcohol use during the course of trastuzumab treatment and the HER2 Ile/Val genotype may constitute risk factors for cardiac toxicity. Source